Association between serum 25(OH)D and death from prostate cancer

Area of Science:

• Oncology
• Endocrinology
• Nutritional Science

Background:

• Vitamin D's role in cancer progression is suggested by varying mortality rates linked to sun exposure.
• Serum 25-hydroxyvitamin D (25(OH)D) levels are investigated for their association with prostate cancer outcomes.

Purpose of the Study:

• To determine if serum 25(OH)D levels correlate with prognosis in prostate cancer patients.
• To assess vitamin D's potential as a prognostic marker in prostate cancer.

Main Methods:

• A cohort of 160 prostate cancer patients with available serum samples was analyzed.
• Serum 25(OH)D levels were categorized as low (<50 nmol/l), medium (50-80 nmol/l), or high (>80 nmol/l).
• Cox proportional hazard regression was employed to evaluate the association between 25(OH)D levels and cancer mortality.

Main Results:

• A significant association was found between medium/high serum 25(OH)D levels and improved prognosis.
• Patients with medium or high 25(OH)D levels had a substantially lower risk of cancer mortality compared to those with low levels (RR 0.33 and 0.16, respectively).
• The association was stronger in patients who had received hormone therapy prior to blood collection.

Conclusions:

• Serum 25(OH)D levels appear to be involved in prostate cancer progression.
• Vitamin D status, indicated by serum 25(OH)D, may serve as a valuable prognostic marker for prostate cancer patients.